Default Category
-
Fútbol Club Barcelona: El tiki-taka en quiebra
Duro, Miguel; Soler, Edi; Rivera de Asis, JavierCase C-796Accounting and Control, Corporate Governance, FinanceSandro Rosell, el nuevo presidente del Fútbol Club Barcelona (FCB), había tomado posesión del cargo el 1 de julio de 2010, un día después de que la anterior Junta y su presidente, Joan Laporta, formulasen las cuentas de la temporada 2009/2010, que abarcaba del 1 de julio de 2009 al 30 de junio de 2010. Pocas semanas después de la formulación de las cuentas por parte de la Junta de Laporta, Rosell y su Junta habían realizado una reformulación de d...Starting at €8.20
-
Futbol Club Barcelona: "Tiki-Taka" Gone Bust
Duro, Miguel; Soler, Edi; Rivera de Asis, JavierCase C-796-EAccounting and Control, Corporate Governance, FinanceAlexandre (Sandro) Rosell, the new president of Futbol Club Barcelona (FCB), took office on July 1, 2010, one day after the previous board and its president, Joan Laporta, had presented the club's financial reports for the 2009/10 season, which covered July 1, 2009 to June 30, 2010. A few weeks after the annual accounts report was released by Laporta's board, Rosell and his board reformulated it. The reformulation made negative adjustments of mor...Starting at €8.20
-
Dr. Reddy's Laboratories (B)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M065-EStrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74
-
Dr. Reddy's Laboratories (A)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M064-EStrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Boehringer Ingelheim: Leading Innovation
J. Robert Mitchell; Ramasastry ChandrasekharCase IVEY-9B14M168-EEntrepreneurship, StrategyThe newly appointed director of Innovation Management & Strategy at Boehringer Ingelheim, a German-based multinational pharmaceutical company, is finding his way forward in his firm’s new, first-of-its-kind role, which is central to the company’s growth rejuvenation strategy. His job has a threefold mandate: to build internal networks, to establish internal structures and to leverage internal ideas. His biggest challenge, however, may be transfor...Starting at €8.20
-
Vidrala 2017: Deciphering Its Annual Report
Duro, MiguelCase C-814-EAccounting and ControlThis is a descriptive case. We will use Vidrala's Financial Statements throughout to learn how to read, analyse and interpret a real company's annual report. The objective of this case is to show students the importance of mastering the underlying accounting measurement and policies in financial statements to be able to enhance their understanding of financial statements, and in turn, to be able to analyse the business in question. The structure ...Starting at €8.20
-
Volkswagen Strategy 2025: Shifting Gears in Disruptive Times
Andreas Schotter; Thomas Watson; Ramasastry ChandrasekharCase IVEY-9B19M047-EStrategyIn 2018, Volkswagen Group’s newly appointed chief executive officer renewed the company’s commitment to Strategy 2025, an ongoing plan intended to radically transform the German automaker. Volkswagen was being challenged by tectonic changes in the automotive industry, including the phasing out of the long-standing internal combustion engine, ongoing digitization, the entry of new competition from technology companies, the introduction of electric...Starting at €8.20
-
Dr. Reddy's Laboratories (A) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS64StrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Dr. Reddy's Laboratories (B) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS65StrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74